DelveInsight’s comprehensive “Frontotemporal Dementia Pipeline Insight 2025” report delivers extensive analysis of more than 15 pharmaceutical companies and over 20 investigational drugs currently in the Frontotemporal Dementia development pipeline. The report encompasses detailed profiles of Frontotemporal Dementia treatment candidates spanning both clinical and preclinical development phases. Additionally, it includes thorough evaluation of Frontotemporal Dementia therapeutics organized by product classification, developmental stage, administration method, and molecular structure. The report also identifies dormant pipeline candidates in this therapeutic space.
Interested in the most recent developments in Frontotemporal Dementia drug development? Discover the breakthrough treatments and clinical studies @ Frontotemporal Dementia Pipeline Outlook Report
Major Highlights from the Frontotemporal Dementia Pipeline Analysis
- On October 24, 2025, Passage Bio Inc. initiated an investigation to evaluate the safety profile, tolerability, and therapeutic effectiveness of this intervention in individuals with frontotemporal dementia carrying mutations in the granulin precursor (GRN) or chromosome 9 open reading frame 72 (C9ORF72) genes.
- On October 15, 2025, Azafaros A.G. launched a Phase 3 investigation to assess the safety profile and therapeutic effectiveness of oral nizubaglustat (AZ-3102) in late-infantile and juvenile variants of Niemann-Pick type C disease and in late-infantile and juvenile-onset variants of GM1 gangliosidosis or GM2 gangliosidosis.
- DelveInsight’s Frontotemporal Dementia Pipeline analysis reveals a dynamic landscape featuring over 15 active pharmaceutical developers advancing more than 20 investigational treatments for Frontotemporal Dementia.
- Key Frontotemporal Dementia developers include Alector, GSK, Eli Lilly and Company, Transposon Therapeutics, Passage Bio, AviadoBio, Vesper Bio, Neurimmune Therapeutics, Asceneuron SA, among others.
- Notable Frontotemporal Dementia treatment candidates comprise LY3884963, Methylprednisolone, Optional Sirolimus, DNL593, AL001, Vortioxetine, PBFT02, galantamine hydrobromide, among others.
Curious about which pharmaceutical companies are driving innovation in Frontotemporal Dementia research? Explore comprehensive pipeline analysis @ Frontotemporal Dementia Clinical Trials Assessment
Report Overview
The Frontotemporal Dementia Pipeline Analysis delivers disease background, pipeline landscape, and therapeutic evaluation of leading investigational treatments in this field. The report additionally emphasizes unmet medical needs regarding Frontotemporal Dementia development.
Understanding Frontotemporal Dementia
Frontotemporal Dementia (FTD) encompasses a group of related disorders stemming from progressive deterioration of the frontal and temporal lobes of the brain. These brain regions are crucial for behavior control, language processing, and decision-making capabilities. FTD is classified as a young-onset dementia, typically manifesting between ages 45-65 and represents the most prevalent dementia type in individuals under 60 years. It presents clinical manifestations that may be confused with other dementia types or psychiatric conditions. The average duration from initial symptom presentation to accurate diagnosis is approximately 3.6 years. The accumulation of misfolded, dysfunctional proteins in particular brain areas is a shared characteristic across numerous neurological conditions and serves as a pathologic marker.
Frontotemporal Dementia Investigational Drug Profiles
AL001: Alector/ GSK
Alector Inc. commenced development of a Sortilin inhibitor AL001 for Frontotemporal Dementia management. AL001 represents a recombinant human anti-human sortilin (SORT1) monoclonal IgG1 created by Alector in partnership with GSK. It seeks to elevate progranulin levels in humans by blocking a progranulin degradation pathway. The antibody secured orphan drug designation, fast track designation, and breakthrough designation from the US FDA for frontotemporal dementia treatment. In July 2021, GSK and Alector established a global partnership for development and commercialization of two monoclonal antibodies (AL001 and AL101) engineered to increase progranulin (PGRN) levels. The organization currently investigates AL001 in Phase III clinical trials for FTD with a C9orf72 mutation and granulin mutation.
TPN-101: Transposon Therapeutics
TPN-101 selectively inhibits the LINE-1 reverse transcriptase that facilitates LINE-1 replication. LINE-1 elements constitute a class of retrotransposable elements that in humans possess unique capability to replicate and relocate to new genomic positions. When this mechanism becomes dysregulated, LINE-1 reverse transcriptase drives excessive LINE-1 DNA production, triggering innate immune reactions that contribute to neurodegenerative, autoimmune, and aging-related disease pathology. Presently, the drug undergoes Phase II evaluation for Frontotemporal Dementia treatment.
AVB-101: AviadoBio
AVB-101 represents a potential single-administration therapy engineered to halt disease progression by delivering a functional GRN gene copy to restore adequate progranulin levels to affected brain regions. The drug is administered using a minimally invasive, stereotactic neurosurgical approach directly to the thalamus portion of the brain. The thalamus maintains extensive connections to other brain regions, including the frontal and temporal lobes, which play a vital role in FTD and the symptoms affecting patients and their families. This targeted delivery approach aims to safely and effectively penetrate the blood-brain barrier, delivering focused treatment directly to the brain to restore progranulin levels in the frontal and temporal cortex where most needed, while simultaneously minimizing required dosage and thereby limiting potential systemic exposure. In November 2023, the US Food and Drug Administration (FDA) awarded Fast Track designation to AVB-101. Presently, the drug undergoes Phase I/II evaluation for Frontotemporal Dementia treatment.
PBFT02: Passage Bio
It represents a gene therapy product candidate, an AAV1 viral vector designed to deliver modified DNA encoding the granulin gene (GRN) to patient cells. The vector will be administered directly to the cerebrospinal fluid through a single injection to the cisterna magna (ICM injection). The objective of this vector and delivery strategy is to provide higher-than-normal progranulin protein (PGRN) levels to the CNS to compensate for progranulin deficiency in GRN gene mutation carriers. Presently, the drug undergoes Phase I/II evaluation for Frontotemporal Dementia treatment.
Key Insights from the Frontotemporal Dementia Pipeline Report
The report delivers comprehensive information regarding:
- Pharmaceutical companies developing treatments for Frontotemporal Dementia management, including total therapeutic candidates from each organization.
- Multiple investigational candidates organized across early-phase, mid-phase, and late-phase development for Frontotemporal Dementia therapy.
- Frontotemporal Dementia pharmaceutical companies pursuing targeted therapeutic development, including both active and inactive (suspended or terminated) programs.
- Frontotemporal Dementia investigational drugs categorized by development phase, administration route, target receptor, monotherapy versus combination therapy, mechanism of action, and molecular classification.
- In-depth examination of partnerships (pharmaceutical-pharmaceutical and pharmaceutical-academic collaborations), licensing arrangements, and funding details for future Frontotemporal Dementia market progression.
If you’re monitoring active Frontotemporal Dementia clinical investigations, this analysis provides essential information. Access breakthrough discoveries @ Frontotemporal Dementia Treatment Drugs
Frontotemporal Dementia Pharmaceutical Companies
Alector, GSK, Eli Lilly and Company, Transposon Therapeutics, Passage Bio, AviadoBio, Vesper Bio, Neurimmune Therapeutics, Asceneuron SA, among others.
Frontotemporal Dementia Pipeline Report: Therapeutic Classification by Administration Route
Investigational products have been organized under multiple administration routes including:
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Frontotemporal Dementia Products: Molecular Classification
Candidates have been grouped under various molecular categories including:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
From emerging treatment candidates to market intelligence, the Frontotemporal Dementia Pipeline Analysis provides complete coverage – access it today @ Frontotemporal Dementia Market Drivers and Barriers, and Future Perspectives
Report Scope
- Coverage: Global
- Frontotemporal Dementia Pharmaceutical Companies: Alector, GSK, Eli Lilly and Company, Transposon Therapeutics, Passage Bio, AviadoBio, Vesper Bio, Neurimmune Therapeutics, Asceneuron SA, among others.
- Frontotemporal Dementia Investigational Therapies: LY3884963, Methylprednisolone, Optional Sirolimus, DNL593, AL001, Vortioxetine, PBFT02, galantamine hydrobromide, among others.
- Frontotemporal Dementia Therapeutic Classification by Product Type: Mono, Combination, Mono/Combination
- Frontotemporal Dementia Therapeutic Classification by Clinical Phases: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay informed about research developments – uncover upcoming trends in Frontotemporal Dementia treatment landscape through detailed analysis @ Frontotemporal Dementia Emerging Drugs and Major Players
Report Contents
* Introduction
* Executive Summary
* Frontotemporal Dementia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Frontotemporal Dementia- DelveInsight’s Analytical Perspective
* Late Stage Products (Phase III)
* AL001: Alector/ GSK
* Drug profiles in the detailed report…..
* Mid Stage Products (Phase II)
* TPN-101: Transposon Therapeutics
* Drug profiles in the detailed report…..
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report…..
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report…..
* Inactive Products
* Frontotemporal Dementia Key Companies
* Frontotemporal Dementia Key Products
* Frontotemporal Dementia- Unmet Needs
* Frontotemporal Dementia- Market Drivers and Barriers
* Frontotemporal Dementia- Future Perspectives and Conclusion
* Frontotemporal Dementia Analyst Views
* Frontotemporal Dementia Key Companies
* Appendix
About Us
DelveInsight represents a premier healthcare-focused market research and advisory firm delivering superior market intelligence and strategic analysis to support evidence-based business decisions. Supported by seasoned industry specialists and comprehensive understanding of life sciences and healthcare industries, we deliver tailored research solutions and strategic insights to international clients. Engage with us to obtain superior, precise, and current intelligence for maintaining competitive advantage.
Contact Us
Kanishk
kkumar@delveinsight.com